Authors
Latest:
Dr Stokes on Radiation Vs Surgery in HPV+ OPSCCWilliam (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.
Latest:
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and ClassificationChristopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian CancerPaul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.
Latest:
Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal CancerI-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.
Latest:
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPCNeil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Latest:
Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian CancerKala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.
Latest:
Seeing Medicine Through the Eye of an ArtistFor many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.
Latest:
Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple MyelomaFrancesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.
Latest:
Dr Leslie on the Significance of the FDA Approval of Pirtobrutinib in Pretreated CLL and SLLLori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Dr Pantin on the Evolving Treatment Paradigm in PNHJeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal ResectionRosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Latest:
Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCLSaurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
Latest:
Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and MoreZarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.
Latest:
Patients With Cancer in Alabama 'Being Robbed of the Choice to Build a Family After Treatment'A consequence of the Alabama Supreme Court’s in vitro fertilization ruling is an unacceptably high risk of infertility for patients with cancer.
Latest:
Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer CenterLeading cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.
Latest:
Future Perspectives in Biomarker Identification and Testing in MMShaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.
